EA200500289A1 - Арилзамещенные бензимидазолы и их использование в качестве блокаторов натриевых каналов - Google Patents

Арилзамещенные бензимидазолы и их использование в качестве блокаторов натриевых каналов

Info

Publication number
EA200500289A1
EA200500289A1 EA200500289A EA200500289A EA200500289A1 EA 200500289 A1 EA200500289 A1 EA 200500289A1 EA 200500289 A EA200500289 A EA 200500289A EA 200500289 A EA200500289 A EA 200500289A EA 200500289 A1 EA200500289 A1 EA 200500289A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
prevention
substituted benzimidazoles
blocators
aryl substituted
Prior art date
Application number
EA200500289A
Other languages
English (en)
Inventor
Кван Сан
Ксиаоминг Жу
Доналд Дж. Кайл
Original Assignee
Еуро-Селтик С. А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Еуро-Селтик С. А. filed Critical Еуро-Селтик С. А.
Publication of EA200500289A1 publication Critical patent/EA200500289A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Настоящее изобретение относится к арилзамещенным бензимидазолам формулы (I) или их фармацевтически приемлемым солям, пролекарствам или сольватам, в которых R, R, Rи n определены в патентном описании. Изобретение также предлагает применение соединений формулы (I) для лечения нейронных повреждений, сопровождающих глобальную и фокальную ишемию, для лечения и профилактики нейродегенеративных заболеваний, например амиотрофического латерального склероза (ALS), и для лечения, профилактики или компенсации острой и хронической боли, как средство от звона в ушах, противосудорожное средство и антидепрессант, как локальный анестетик, антиаритмическое средство и для лечения или профилактики диабетической нейропатии.Отчет о международном поиске был опубликован 2004.04.01.
EA200500289A 2002-07-31 2003-07-31 Арилзамещенные бензимидазолы и их использование в качестве блокаторов натриевых каналов EA200500289A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39945802P 2002-07-31 2002-07-31
PCT/US2003/023828 WO2004011439A2 (en) 2002-07-31 2003-07-31 Aryl substituted benzimidazoles and their use as sodium channel blockers

Publications (1)

Publication Number Publication Date
EA200500289A1 true EA200500289A1 (ru) 2005-06-30

Family

ID=31188586

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200500289A EA200500289A1 (ru) 2002-07-31 2003-07-31 Арилзамещенные бензимидазолы и их использование в качестве блокаторов натриевых каналов

Country Status (13)

Country Link
US (1) US7022714B2 (ru)
EP (1) EP1532119A2 (ru)
JP (1) JP2006504660A (ru)
KR (1) KR20050026031A (ru)
CN (1) CN1671672A (ru)
AU (1) AU2003257033A1 (ru)
BR (1) BR0313352A (ru)
CA (1) CA2492305A1 (ru)
EA (1) EA200500289A1 (ru)
IL (1) IL166366A0 (ru)
MX (1) MXPA05000812A (ru)
NO (1) NO20051066L (ru)
WO (1) WO2004011439A2 (ru)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2522562C (en) 2003-04-17 2013-09-03 Janssen Pharmaceutica N.V. 2-phenyl-benzimidazol and 2-phenyl-imidazo-`4,5!-pyridine derivatives as checkpoint kinase cds1 (chk2) inhibitors for the treatment of cancer
US7157471B2 (en) * 2003-08-25 2007-01-02 Boehringer Ingelheim International Gmbh Haloalkyl- and piperidine-substituted benzimidazole-derivatives
KR20060087386A (ko) 2005-01-28 2006-08-02 주식회사 대웅제약 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물
EP1861387B1 (en) * 2005-01-28 2014-04-16 Daewoong Pharmaceutical Co., Ltd. Benzimidazole derivatives and pharmaceutical compositions thereof
JP5054770B2 (ja) * 2006-07-11 2012-10-24 デウン ファーマシューティカル カンパニー リミテッド 新規のビアリールベンゾイミダゾール誘導体及びこれを含む医薬組成物
EP2582666B1 (en) * 2010-06-16 2014-08-13 Purdue Pharma L.P. Aryl substituted indoles and their use as blockers of sodium channels
WO2012007836A1 (en) 2010-07-16 2012-01-19 Purdue Pharma .Lp. Pyridine compounds as sodium channel blockers
US9056832B2 (en) 2010-09-17 2015-06-16 Purdue Pharma L.P. Pyridine compounds and the users thereof
EP2621915B1 (en) 2010-09-28 2016-04-20 Daewoong Pharmaceutical Co., Ltd Novel method of preparing benzoimidazole derivatives
ES2540562T3 (es) 2010-10-05 2015-07-10 Purdue Pharma L.P. Compuestos de quinazolina como bloqueadores de canales de sodio
AU2011346751A1 (en) 2010-12-22 2013-05-02 Purdue Pharma L.P. Substituted pyridines as sodium channel blockers
WO2013030665A1 (en) 2011-09-02 2013-03-07 Purdue Pharma L.P. Pyrimidines as sodium channel blockers
US9388137B2 (en) 2011-10-31 2016-07-12 Purdue Pharma L.P. Quaternized amines as sodium channel blockers
WO2013064883A1 (en) 2011-10-31 2013-05-10 Purdue Pharma L.P. Heteroaryl compounds as sodium channel blockers
WO2013072758A1 (en) 2011-11-15 2013-05-23 Purdue Pharma L.P. Pyrimidine diol amides as sodium channel blockers
WO2013114250A1 (en) * 2012-02-03 2013-08-08 Pfizer Inc. Benziimidazole and imidazopyridine derivatives as sodium channel modulators
US9206127B2 (en) 2012-03-16 2015-12-08 Purdue Pharm, L.P. Substituted pyridines as sodium channel blockers
UA115576C2 (uk) * 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
EP2935257B1 (en) 2012-12-20 2018-02-07 Purdue Pharma LP Cyclic sulfonamides as sodium channel blockers
US9120786B2 (en) 2013-03-04 2015-09-01 Purdue Pharma, L.P. Triazine carboxamides as sodium channel blockers
WO2014135955A1 (en) 2013-03-04 2014-09-12 Purdue Pharma L.P. Pyrimidine carboxamides as sodium channel blockers
CA2939549C (en) 2013-03-15 2020-08-18 Purdue Pharma L.P. Carboxamide derivatives and use thereof
CA2922567A1 (en) 2013-08-26 2015-03-05 Purdue Pharma L.P. Azaspiro[4.5]decane derivatives and use thereof
US9359330B2 (en) 2013-08-26 2016-06-07 Purdue Pharma L.P. Substituted piperidines as sodium channel blockers
US9828348B2 (en) 2013-11-08 2017-11-28 Purdue Pharma L.P. Benzimidazole derivatives and use thereof
US9340504B2 (en) 2013-11-21 2016-05-17 Purdue Pharma L.P. Pyridine and piperidine derivatives as novel sodium channel blockers
TW201607943A (zh) * 2013-12-19 2016-03-01 拜耳製藥公司 作為ｅｐ４配體之新穎苯并咪唑衍生物
US9745287B2 (en) 2013-12-20 2017-08-29 Purdue Pharma L.P. Pyrimidines and use thereof
CN106103415B (zh) 2013-12-23 2023-02-24 普渡制药公司 吲唑和其用途
US9695144B2 (en) 2013-12-23 2017-07-04 Purdue Pharma L.P. Dibenzazepine derivatives and use thereof
EP3089978B1 (en) 2013-12-30 2018-08-29 Purdue Pharma L.P. Pyridone-sulfone morphinan analogs as opioid receptor ligands
EP3097078B1 (en) 2014-01-24 2022-05-25 Purdue Pharma LP Pyridines and pyrimidines and use thereof
CN106103422B (zh) 2014-02-12 2020-09-18 普渡制药公司 异喹啉衍生物及其用途
US10730866B2 (en) 2014-04-07 2020-08-04 Purdue Pharma L.P. Indole derivatives and use thereof
US9975854B2 (en) 2014-05-06 2018-05-22 Purdue Pharma L.P. Benzomorphan analogs and use thereof
WO2015192053A1 (en) 2014-06-13 2015-12-17 Purdue Pharma L.P. Azamophinan derivatives and use thereof
MA40170A (fr) 2014-06-13 2017-04-19 Purdue Pharma Lp Dérivés hétérocycliques de morphinan et leur utilisation
AU2016219879A1 (en) 2015-02-19 2017-08-24 Purdue Pharma L.P. Methods and compositions for decreasing gastric emptying

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4297365A (en) * 1978-08-04 1981-10-27 Ciba-Geigy Corporation Benzimidazoles and pharmaceutical preparations containing such compounds
EP0922028A1 (en) 1996-08-26 1999-06-16 Genetics Institute, Inc. Inhibitors of phospholipase enzymes
AU3297099A (en) 1998-02-25 1999-09-15 Genetics Institute Inc. Inhibitors of phospholipase a2
US6211177B1 (en) 1998-11-24 2001-04-03 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives
BR0009322A (pt) 1999-03-26 2002-04-30 Euro Celtique Sa Pirazóis, imidazóis, oxazóis, tiazóis e pirróis substituìdos com arila e o uso dos mesmos
JP2000323278A (ja) 1999-05-14 2000-11-24 Toray Ind Inc 発光素子
WO2001021634A1 (en) 1999-09-21 2001-03-29 Lion Bioscience Ag Benzimidazole derivatives and combinatorial libraries thereof
AR029489A1 (es) 2000-03-10 2003-07-02 Euro Celtique Sa Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento
BR0108819A (pt) 2000-03-24 2002-12-10 Euro Celtique Sa Pirazóis triazóis e tetrazóis substituìdos de arila, e o uso dos mesmos
AU2001249610B2 (en) 2000-03-31 2005-03-24 Euro-Celtique S.A. Aminopyridines and their use as anticonvulsants and sodium channel blockers
AU5919001A (en) 2000-04-28 2001-11-12 Acadia Pharm Inc Muscarinic agonists
GB0017256D0 (en) 2000-07-13 2000-08-30 Merck Sharp & Dohme Therapeutic agents
JP2004538285A (ja) 2001-07-16 2004-12-24 ユーロ−セルティック エス． ア． アリール置換チアゾリジノンおよびその使用
AR036873A1 (es) 2001-09-07 2004-10-13 Euro Celtique Sa Piridinas aril sustituidas a, composiciones farmaceuticas y el uso de las mismas para la preparacion de un medicamento
AR037233A1 (es) 2001-09-07 2004-11-03 Euro Celtique Sa Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento
ATE434610T1 (de) 2002-03-13 2009-07-15 Euro Celtique Sa Aryl substituierte pyrimidine und deren verwendung

Also Published As

Publication number Publication date
EP1532119A2 (en) 2005-05-25
JP2006504660A (ja) 2006-02-09
WO2004011439A2 (en) 2004-02-05
BR0313352A (pt) 2005-07-12
CA2492305A1 (en) 2004-02-05
NO20051066L (no) 2005-02-25
CN1671672A (zh) 2005-09-21
AU2003257033A1 (en) 2004-02-16
US7022714B2 (en) 2006-04-04
WO2004011439A3 (en) 2004-04-01
US20040132777A1 (en) 2004-07-08
MXPA05000812A (es) 2005-04-19
IL166366A0 (en) 2006-01-16
KR20050026031A (ko) 2005-03-14

Similar Documents

Publication Publication Date Title
EA200500289A1 (ru) Арилзамещенные бензимидазолы и их использование в качестве блокаторов натриевых каналов
EA200500174A1 (ru) Новые производные бензимидазола, полезные в качестве антипролиферативных агентов
MX2007004183A (es) Derivados de benzoimidazol utiles como agentes antiproliferacion.
CY1109355T1 (el) Πυριμιδινες υποκατεστημενες με αρυλιο και η χρηση αυτων
EA200500018A1 (ru) Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения
EA200702339A1 (ru) Замещенные амидные производные в качестве ингибиторов протеинкиназы
HRP20070505B1 (hr) Spiro-oksindol spojevi i njihove upotrebe kao terapijska sredstva
ATE440603T1 (de) 8-hydroxychinolinderivate
EA200300788A1 (ru) Производные замещенных алкиламинов и их применение
ECSP055719A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos
EA200200716A1 (ru) Арилконденсированные азаполициклические соединения
ATE368031T1 (de) Neue gamma secretase inhibitoren
TNSN07349A1 (fr) Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
YU67902A (sh) Aril supstituisani piridini, pirimidini, pirazini i triazini i njihova upotreba
ATE360631T1 (de) Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors
ECSP034809A (es) Ciclobuteno-1,2-dionas 3,4-disustituidas como ligandos del receptor de quimocina cxc
EA200901373A1 (ru) Аминогетероциклические соединения
EA200501098A1 (ru) Антибактериальные агенты
EA200900613A1 (ru) Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
EA200801041A1 (ru) Ингибиторы мек и способы их применения
CY1107956T1 (el) Χρηση υποκατεστημενων 2-αμινοτετραλινιων για την προληπτικη αντιμετωπιση της νοσου του παρκινσον
BR0313084A (pt) Composto, composição farmacêutica, método para a produção de um composto, método de tratamento, prevenção ou melhora de uma desordem, e método de tratamento de um mamìfero